Comparative Pharmacology
Head-to-head clinical analysis: LESSINA 21 versus SYEDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LESSINA 21 versus SYEDA.
LESSINA-21 vs SYEDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.
Syeda is a combination of drospirenone and ethinyl estradiol, a contraceptive that suppresses gonadotropins, primarily inhibiting ovulation; drospirenone has antimineralocorticoid and antiandrogenic activity.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.
1 tablet (3 mg drospirenone / 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
17-21 hours (terminal elimination half-life; clinical significance: allows once-daily dosing, but missed doses increase risk of ovulation)
Terminal elimination half-life of 12-15 hours; allows twice-daily dosing for sustained therapeutic levels.
Renal (70% as unchanged drug and metabolites), fecal (30% as metabolites)
Urinary excretion (40-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for 15-25%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive